

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2021 June 14; 27(22): 2921-3141



### FRONTIER

- 2921** Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21<sup>st</sup> century  
*El-Salhy M, Patcharatrakul T, Gonlachanvit S*

### REVIEW

- 2944** Interplay between nuclear factor erythroid 2-related factor 2 and inflammatory mediators in COVID-19-related liver injury  
*Zhu DD, Tan XM, Lu LQ, Yu SJ, Jian RL, Liang XF, Liao YX, Fan W, Barbier-Torres L, Yang A, Yang HP, Liu T*
- 2963** Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review  
*Sun Y, Zhang Z, Zheng CQ, Sang LX*
- 2979** Application of artificial intelligence-driven endoscopic screening and diagnosis of gastric cancer  
*Hsiao YJ, Wen YC, Lai WY, Lin YY, Yang YP, Chien Y, Yarmishyn AA, Hwang DK, Lin TC, Chang YC, Lin TY, Chang KJ, Chiou SH, Jheng YC*
- 2994** Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment  
*Granito A, Muratori L, Lalanne C, Quarneri C, Ferri S, Guidi M, Lenzi M, Muratori P*

### MINIREVIEWS

- 3010** Role of bile acids in liver diseases mediated by the gut microbiome  
*Shao JW, Ge TT, Chen SZ, Wang G, Yang Q, Huang CH, Xu LC, Chen Z*
- 3022** Liver injury in COVID-19: Detection, pathogenesis, and treatment  
*Cai Y, Ye LP, Song YQ, Mao XL, Wang L, Jiang YZ, Que WT, Li SW*
- 3037** Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma  
*Zhang Y, Huang ZX, Song B*
- 3050** Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis  
*Moran S, López-Sánchez M, Milke-García MDP, Rodríguez-Leal G*
- 3064** COVID-19 and pediatric fatty liver disease: Is there interplay?  
*Di Sessa A, Lanzaro F, Zarrilli S, Picone V, Guarino S, Miraglia del Giudice E, Marzuillo P*

## ORIGINAL ARTICLE

## Basic Study

- 3073 Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease

*Zhou J, Yang Y, Wang YL, Zhao Y, Ye WJ, Deng SY, Lang JY, Lu S*

## Retrospective Study

- 3085 Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival

*Jiang ZN, Ahmed SMU, Wang QC, Shi HF, Tang XW*

- 3097 Idiopathic mesenteric phleboscrosis associated with long-term oral intake of geniposide

*Wen Y, Chen YW, Meng AH, Zhao M, Fang SH, Ma YQ*

- 3109 Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome

*Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K*

## Observational Study

- 3121 Preservation of superior rectal artery in laparoscopically assisted subtotal colectomy with ileorectal anastomosis for slow transit constipation

*Wu CW, Pu TW, Kang JC, Hsiao CW, Chen CY, Hu JM, Lin KH, Lin TC*

## Prospective Study

- 3130 High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study

*Zerbato V, Di Bella S, Giuffrè M, Jaracz AW, Gobbo Y, Luppino D, Macor P, Segat L, Koncan R, D'Agaro P, Valentini M, Crocé LS, Ruscio M, Luzzati R*

## CORRECTION

- 3138 *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression

*Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B, Li YM*

## ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Francisco Rodriguez-Frias, MS, PhD, Senior Investigator, Associate Professor at Sciences and Medicine Schools, Autonomía University of Barcelona; Head of Special Units (Biochemistry Department) and Head of Liver Pathology Laboratory (Biochemistry and Microbiology Departments) of Vall d'Hebron University Hospital; Head of Biochemistry Research Group of Vall d'Hebron Institute of Research, Passeig Vall d'Hebron, 119-129, Barcelona 08035, Spain. [frarodri@vhebron.net](mailto:frarodri@vhebron.net)

## AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

## INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2019 is 7.1 and Scopus CiteScore rank 2019: Gastroenterology is 17/137.

## RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ji-Hong Lin; Production Department Director: Yun-Xiaojuan Wu; Editorial Office Director: Ze-Mao Gong.

### NAME OF JOURNAL

*World Journal of Gastroenterology*

### ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

### LAUNCH DATE

October 1, 1995

### FREQUENCY

Weekly

### EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

### EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

### PUBLICATION DATE

June 14, 2021

### COPYRIGHT

© 2021 Baishideng Publishing Group Inc

### INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

### GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

### GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

### PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

### PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

### ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

### STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

### ONLINE SUBMISSION

<https://www.f6publishing.com>



## *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression

Li-Ping Liu, Xi-Ping Sheng, Tian-Kui Shuai, Yong-Xun Zhao, Bin Li, Yu-Min Li

**ORCID number:** Li-Ping Liu 0000-0002-8339-0256; Xi-Ping Sheng 0000-0001-9641-7633; Tian-Kui Shuai 0000-0001-6733-3377; Yong-Xun Zhao 0000-0001-9448-1623; Bin Li 0000-0002-7366-4997; Yu-Min Li 0000-0002-9267-1412.

**Author contributions:** Liu LP and Li YM designed the experiments; Sheng XP and Li B contributed to the statistical analyses; Zhao YX performed the experiments; Liu LP prepared the manuscript; Shuai TK and Li B conducted data collection.

**Conflict-of-interest statement:** The authors declare that they have no competing interests to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Li-Ping Liu**, The Second Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730000, Gansu Province, China

**Li-Ping Liu, Bin Li**, Department of Critical Care Medicine, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China

**Li-Ping Liu, Tian-Kui Shuai**, Department of Critical Care Medicine, The Donggang District of First Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China

**Xi-Ping Sheng**, Institute of Epidemiology and Health Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, Gansu Province, China

**Yong-Xun Zhao**, Department of Surgical Oncology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China

**Yu-Min Li**, Key Laboratory of Digestive System Tumors of Gansu Province, The Second Clinical Medical School of Lanzhou University, Lanzhou 730000, Gansu Province, China

**Corresponding author:** Yu-Min Li, MD, PhD, Chief Doctor, Professor, Key Laboratory of Digestive System Tumors of Gansu Province, The Second Clinical Medical School of Lanzhou University, No. 82 Cuiyingmen, Chengguan District, Lanzhou 730000, Gansu Province, China. [liymin@lzu.edu.cn](mailto:liymin@lzu.edu.cn)

### Abstract

Correction to "Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B, Li YM. *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression. *World J Gastroenterol* 2018; 24: 4565-4577 [PMID: 30386106 DOI: 10.3748/wjg.v24.i40.4565]." In this article, we have identified some of the images in Figure 2A, C, E, G, and I are identical to the images in Figures 1B, 2A, 3B, 3E, and 3G of another paper entitled "Liu L, Zhao Y, Fan G, Shuai T, Li B, Li Y. *Helicobacter pylori* infection enhances heparanase leading to cell proliferation via mitogenactivated protein kinase signalling in human gastric cancer cells.", which was published by us in the *Molecular Medicine Reports* in December, 2018 [PMID: 30320396 DOI: 10.3892/mmr.2018.9558]. The reason why we asked to replace the pictures was that when we were simultaneously preparing to submit our two different articles to the *World Journal of Gastroenterology* (WJG) and *Molecular Medicine Reports*, we uploaded the wrong pictures to the WJG, which were same as those submitted to the *Molecular Medicine Reports*. We apologize for this negligence and any inconvenience that this may cause. We would be grateful if

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Received:** January 6, 2021

**Peer-review started:** January 6, 2021

**First decision:** February 11, 2021

**Revised:** February 19, 2021

**Accepted:** May 17, 2021

**Article in press:** May 17, 2021

**Published online:** June 14, 2021

**P-Reviewer:** Shimada S

**S-Editor:** Fan JR

**L-Editor:** Wang TQ

**P-Editor:** Liu JH



you could replace the wrong pictures with the correct ones attached.

**Key Words:** Correction; Replace the wrong pictures; Gastric cancer; *Helicobacter pylori*

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** This manuscript is to correct the images in Figure 2A, C, E, G, and I of "Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B, Li YM. *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression. *World J Gastroenterol* 2018; 24: 4565-4577 [PMID: 30386106 DOI: 10.3748/wjg.v24.i40.4565]."

**Citation:** Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B, Li YM. *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression. *World J Gastroenterol* 2021; 27(22): 3138-3141

**URL:** <https://www.wjgnet.com/1007-9327/full/v27/i22/3138.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v27.i22.3138>

## TO THE EDITOR

### Correction


Correction to: Figure 2A, C, E, G and I. Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B, Li YM. *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression. *World J Gastroenterol* 2018; 24: 4565-4577 [PMID: 30386106 DOI: 10.3748/wjg.v24.i40.4565].

In this article[1], we have identified some of the images in Figure 2A, C, E, G, and I are identical to the images in Figures 1B, 2A, 3B, 3E, and 3G of another paper entitled "Liu L, Zhao Y, Fan G, Shuai T, Li B, Li Y. *Helicobacter pylori* infection enhances heparanase leading to cell proliferation via mitogenactivated protein kinase signalling in human gastric cancer cells"[2], which was published by us in the *Molecular Medicine Reports* in December, 2018.


The reason why we asked to replace the pictures was that when we were simultaneously preparing to submit our two different articles to the *World Journal of Gastroenterology* (WJG) and *Molecular Medicine Reports*, we uploaded the wrong pictures to the WJG, which were same as those submitted to the *Molecular Medicine Reports*.

We apologize for this negligence and any inconvenience that this may cause.

We would be grateful if you could replace the wrong pictures with the correct ones attached (Figure 1).







**Figure 1** Heparanase protein expression following *Helicobacter pylori* infection in MKN-45 gastric cancer cells via the mitogen-activated protein kinase signaling pathway. A: Heparanase (HPA) expression was determined by Western blot at 0, 6, 12, 24, and 48 h after *Helicobacter pylori* (*H. pylori*) infection; B: Quantitative Western blot results of HPA; C: p-p38 mitogen-activated protein kinase (MAPK) expression was determined by Western blot at 0, 30, 60, 120, and 480 min after *H. pylori* infection; D: Quantitative Western blot results of p-p38MAPK; E: HPA expression when the MAPK inhibitor SB203580 was given to MKN-45 cells before *H. pylori* infection; F: Quantitative Western blot results of HPA when the MAPK inhibitor SB203580 was given. <sup>b</sup>*P* < 0.01 compared with the value at 0 h; G and H: Cell invasion rates in the three groups detected using a Transwell invasion assay; I and J: Migration rates in the three groups detected using a scratch migration assay. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01. HPA: Heparanase; MAPK: Mitogen-activated protein kinase; *H. pylori*: *Helicobacter pylori*. Figure 2 in the original manuscript: Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B, Li YM. *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression. *World J Gastroenterol* 2018; 24: 4565-4577 [PMID: 30386106 DOI: 10.3748/wjg.v24.i40.4565].

## ACKNOWLEDGEMENTS

We thank Dr. Zhong-Tian Bai for his critical reading of this manuscript. The authors appreciate Wen-Ting He for technical assistance.

## REFERENCES

- 1 Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B, Li YM. *Helicobacter pylori* promotes invasion and metastasis of gastric cancer by enhancing heparanase expression. *World J Gastroenterol* 2018; 24: 4565-4577 [PMID: 30386106 DOI: 10.3748/wjg.v24.i40.4565]
- 2 Liu L, Zhao Y, Fan G, Shuai T, Li B, Li Y. *Helicobacter pylori* infection enhances heparanase leading to cell proliferation via mitogenactivated protein kinase signalling in human gastric cancer cells. *Mol Med Rep* 2018; 18: 5733-5741 [PMID: 30320396 DOI: 10.3892/mmr.2018.9558]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

